Roquefort Therapeutics plc
LSE: ROQ.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen Paul West
- Employees
- 7
- Headquarters
- London, United Kingdom
- IPO year
- 2021
- Market cap
- £155.5K
- Website
- https://www.roquefortinvest.com
Loading ROQ…
Loading profile data…Frequently asked questions about ROQ
What does Roquefort Therapeutics plc (ROQ.L) do?
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United King...
Where does ROQ.L trade?
Roquefort Therapeutics plc (ROQ.L) trades on the London Stock Exchange.
What sector is ROQ.L in?
Roquefort Therapeutics plc (ROQ.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Roquefort Therapeutics plc?
Stephen Paul West is the chief executive officer of Roquefort Therapeutics plc (ROQ.L).
Where is Roquefort Therapeutics plc headquartered?
Roquefort Therapeutics plc is headquartered in United Kingdom.
Does ROQ.L pay a dividend?
Roquefort Therapeutics plc (ROQ.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ROQ.L go public?
Roquefort Therapeutics plc (ROQ.L) completed its initial public offering in 2021.